Wednesday, the FDA approved Merck & Co Inc’s (NYSE:MRK) Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for the first-line treatment of adult patients with ...

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...

Merck and Siemens have signed a strategic partnership to accelerate digital transformation in manufacturing through smart, ...

The FDA issued draft guidance on oncology clinical trials, taking the first steps toward formalizing a position that it's ...

Here are 10 of the best health care stocks to buy in 2024, according to CFRA analysts: *As of Sept. 10 close. Based on ...

Merck & Co.’s best-selling drug Keytruda helped ... The findings, presented Sunday at the European Society for Medical Oncology Congress in Barcelona, show the initial benefits seen with ...

Healthcare stocks have jumped into pricey territory. Anyone looking to buy in now might want to consider the laggards. The ...

What’s next for Akeso and Summit Therapeutics after their cancer immunotherapy outperformed Merck’s Keytruda in a large Phase 3 clinical trial? Who’s the iconoclastic outsider behind Summit ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Joseph Romanelli, president, Human Health International, is scheduled to participate in a fireside chat at ...

Merck broke down the results Friday at the European Society of Medical Oncology Congress in Barcelona. In an email, the company pointed out that the majority of patients in LITESPARK-005 received ...

Merck (NYSE: MRK) is a top pharmaceutical company coming off a good quarter that shows it is growing its top and bottom lines. Even with that growth, the stock still trades at a fairly modest ...